" class="no-js "lang="en-US"> Meir Jakobsohn - Medtech Alert
Thursday, July 17, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Meir Jakobsohn

Meir Jakobsohn

About Meir Jakobsohn

Meir founded Medison in 1996 and has been serving as its CEO since the company’s inception, spearheading Medison’s growth to become the largest pharma company in Israel, as well as actively expanding into international markets.

Meir is third generation in the pharma industry, starting in 1937 when the Jakobsohn family represented Ciba-Geigy (formerly Novartis), where he served as COO of M. Jakobsohn Ltd.

Meir holds a BA in Economics and Business Administration from Bar Ilan University and an MBA in Business Administration from Bradford University in the UK.

Meir serves on several boards of directors and leads a variety of multiple philanthropic projects focusing on education and social welfare.

Related Story

Diseases

 Hansa Biopharma and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix® in Highly Sensitized Kidney Transplant Patients | Pharmtech Focus

Hansa Biopharma and Medison Pharma Announce Positive Reimbursement Decision in Poland for Idefirix® in Highly Sensitized Kidney Transplant Patients

August 23 2022

Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological […]